Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Verndari
Sacramento, California, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Verndari’s preclinical studies using the VaxiPatch™, a single-dose vaccine kit using intradermal microarray technology, have demonstrated thermostability and higher efficacy compared to traditional vaccine delivery. The main focus has been on infectious diseases, notably with an ongoing COVID-19 vaccine effort[1][3][5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccinemRNA-based drugsDevice
- Industry
- Biotech
Beyond the preview
Go deeper on Verndari.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Verndari.